Please login to the form below

Not currently logged in
Email:
Password:

Biotest makes two senior management appointments

Promotion for Jörg Schüttrumpf while Markus Rothenburger joins from Fresenius Kabi

Markus Rothenburger, Biotest Biotest has promoted Dr Jörg Schüttrumpf to head its global research efforts, while Professor Markus Rothenburger (pictured) will join the company as head of medical/regulatory affairs.

Dr Schüttrumpf only joined the Germany-based biopharma in July 2012, and will now have responsibility for early research and development in Biotest's key areas of focus: immunology, haematology and intensive care.

His career prior to joining Biotest includes positions at Essen und Frankfurt am Main university hospitals as well as at the blood donor service DRK-Blutspendedienst Baden-Württemberg-Hessen.

“He is the ideal candidate to head this important area,” said Biotest's chair Professor Gregor Schulz.

“Dr Schüttrumpf is a specialist in the fields of coagulation research and transfusion medicine, and was therefore our first choice for this position.'

Prof Rothenburger joins Biotest from his role as VP medical and clinical affairs at Fresenius Kabi.

He has also served at Novartis, and has clinical experience in vascular and heart surgery during his time working in hospital.

“We win an excellent medical specialist and a pharmaceutical manager with wide-ranging industry connections,” said Prof Schulz .

19th December 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics